Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice

Area of Science:

• Neuroscience
• Pharmacology
• Cellular Biology

Background:

• Enhanced striatal cholinergic interneuron activity is implicated in Parkinson's disease (PD) and levodopa-induced dyskinesia.
• Severe PD presents challenges with limited therapeutic options, especially concerning debilitating motor fluctuations and dyskinesia.
• Targeting cholinergic interneurons offers a promising alternative to systemic anticholinergics, which can worsen extrastriatal symptoms.

Purpose of the Study:

• To investigate the intrinsic alterations of cholinergic interneurons in a mouse model of PD treated with levodopa.
• To identify molecular mechanisms underlying pathological cholinergic interneuron activity in severe PD with motor fluctuations and dyskinesia.

Main Methods:

• Ex vivo electrophysiological recordings.
• Pharmacological and morphological studies.
• Utilized the 6-hydroxydopamine mouse model of PD.

Main Results:

• Cholinergic interneurons exhibit pathological burst-pause activity in the parkinsonian "off levodopa" state.
• This activity is mediated by persistent, ligand-independent dopamine D1/D5 receptor signaling via a cyclic adenosine monophosphate (cAMP) pathway.
• Dysregulation of inward-rectifier potassium type 2 (Kir2) and leak channels contributes to burst-pause firing, which is reduced by inhibiting intracellular cAMP.

Conclusions:

• Aberrant cholinergic interneuron burst-pause activity in levodopa-treated parkinsonian mice is driven by D5-cAMP signaling and ion channel dysregulation.
• Targeting these pathways may restore normal cholinergic interneuron function, potentially alleviating parkinsonism and dyskinesia.